[1] Keane S, Fabre A, Keane D. Characterization of atrial histology in a patient with hypertrophic cardiomyopathy:
possible evidence of a primary atrial myopathy[J].
HeartRhythm Case Rep, 2021, 7(6):413-417.
[2] Semsarian C, Ingles J, Maron MS, et al. New perspectives on
the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll
Cardiol, 2015, 65(12):1249-1254.
[3] Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive
cardiomyopathy[J]. Lancet, 2017, 389(10075):1253-1267.
[4] Alcalai RO, Seidman JG, Seidman CE. Genetic basis of
hypertrophic cardiomyopathy: from bench to the clinics[J]. J
Cardiovasc Electrophysiol, 2008, 19(1):104-110.
[5] 宋雷, 邹玉宝, 汪道文, 等. 中国成人肥厚型心肌病诊断与治
疗指南[J]. 中华心血管病杂志, 2017, 45(12):1015-1032.
[6] Creta A, Hunter RJ, Earley MJ, et al. Non-vitamin K oral
anticoagulants in hypertrophic cardiomyopathy patients
undergoing catheter ablation of atrial fibrillation[J]. J
Cardiovasc Electrophysiol, 2020, 31(10):2626-2631.
[7] Nasser MF, Gandhi S, Siegel RJ, et al. Anticoagulation
for stroke prevention in patients with hypertrophic
cardiomyopathy and atrial fibrillation: a review[J]. Heart
Rhythm, 2021, 18(2):297-302.
[8] Lee SE, Park JK, Uhm JS, et al. Impact of atrial fibrillation on
the clinical course of apical hypertrophic cardiomyopathy[J].
Heart, 2017, 103(19):1496-1501.
[9] Siontis KC, Geske JB, Ong K, et al. Atrial fibrillation
in hypertrophic cardiomyopathy: prevalence, clinical
correlations, and mortality in a large high-risk population[J]. J
Am Heart Assoc, 2014, 3(3):e001002.
[10] Tsuda T, Hayashi KS, Fujino N, et al. Effect of hypertrophic
cardiomyopathy on the prediction of thromboembolism in
patients with nonvalvular atrial fibrillation[J]. Heart Rhythm,
2019, 16(6):829-837.
[11] Frontera A, Wilson DG, Sekhon H, et al. Atrial fibrillation and
hypertrophic cardiomyopathy: who to anticoagulate?[J]. Clin
Res Cardiol, 2015, 104(10):799-802.
[12] Hindricks G, Potpara T, DagresN,et al. 2020 ESC Guidelines
for the diagnosis and management of atrial fibrillation
developed in collaboration with the European Association
for Cardio-Thoracic Surgery (EACTS)[J].Eur Heart J, 2021,
42(5):373-498.
[13] Zhou YG, He WF, Zhou Y, et al. Non-vitamin K antagonist
oral anticoagulants in patients with hypertrophic
cardiomyopathy and atrial fibrillation: a systematic review and
meta-analysis[J]. J Thromb Thrombolysis, 2020, 50(2):311-
317.
[14] Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA
guideline for the diagnosis and treatment of hypertrophic
cardiomyopathy: a report of the American College of
Cardiology Foundation/American Heart Association
task force on practice guidelines[J]. Circulation, 2011,
124(24):e783-e831.
[15] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC
guidelines on diagnosis and management of hypertrophic
cardiomyopathy: the task force for the diagnosis and
management of hypertrophic cardiomyopathy of the
European society of cardiology (ESC)[J]. Eur Heart J, 2014,
35(39):2733-2779.
[16] Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC
guideline for the diagnosis and treatment of patients with
hypertrophic cardiomyopathy: executive summary: a report
of the American College of Cardiology/American Heart
Association Joint Committee on clinical practice guidelines[J].
Circulation, 2020, 142(25):e533-e557.
[17] Noseworthy PA, Yao AA, Shah ND, et al. Stroke and
bleeding risks in NOAC- and Warfarin-treated patients with
hypertrophic cardiomyopathy and atrial fibrillation[J]. J Am
Coll Cardiol, 2016, 67(25):3020-3021.
[18] Lee HJ, Kim HK, Jung JH, et al. Novel oral anticoagulants
for primary stroke prevention in hypertrophic cardiomyopathy
patients with atrial fibrillation[J]. Stroke, 2019, 50(9):2582-
2586.
[19] Jung H, Yang PS, Jang E, et al. Effectiveness and safety of
non-vitamin K antagonist oral anticoagulants in patients
with atrial fibrillation with hypertrophic cardiomyopathy: a
nationwide cohort study[J]. Chest, 2019, 155(2):354-363.
[20] Dominguez F, Climent V, Zorio E, et al. Direct oral
anticoagulants in patients with hypertrophic cardiomyopathy
and atrial fibrillation[J]. Int J Cardiol, 2017, 248:232-238.
[21] Steffel J, Collins R, Antz M, et al. 2021 European heart
rhythm association practical guide on the use of non-vitamin
K antagonist oral anticoagulants in patients with atrial
fibrillation[J]. Europace, 2021, 23(10):1612-1676.
[22] Bhogal S, Mawa K, Bhandari T, et al. Use of NOACs versus
vitamin K antagonist in atrial fibrillation catheter ablation: an
updated meta-analysis with subgroup analysis[J]. Am J Ther,
2021, 29(1):e56-e63.
[23] Yang Q, Chen XF, Zhai JL, et al. Comparison of major
bleeding events of uninterrupted non-vitamin K antagonist
oral anticoagulants versus uninterrupted vitamin K antagonist
during catheter ablation of atrial fibrillation: a meta-analysis of
randomised controlled trials[J]. Acta Cardiol, 2022, 77(3):257-
263.